Roche jumps into epigenetics with deal for Oryzon's leukemia hopeful

Roche Head of Pharmaceutical Research John Reed

John Reed's Basel-based pRED group at Roche ($RHHBY) has struck its first epigenetics deal with a $500 million-plus potential payoff for Barcelona-based Oryzon and its orphan cancer blocker ORY-1001, now being studied in the clinic for acute myeloid leukemia. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.